For conservative investors in 2019, my top idea is Janus Henderson (JNS); for more risk-oriented inv...
Buy or wait in China? My indicator edges toward buy--ever so slightly
06/16/2010 4:12 pm EST
I’ve repeatedly tabbed this IPO as the indicator I’m watching to figure out the health of China’s stock market in particular and its financial system in general—and to time buys of Chinese stocks.
China’s already publicly traded banks need to raise $40 billion in new capital this year to meet requirements from bank regulators for higher reserve levels and to meet demands from the economy for new loans. The ability of the Agricultural Bank of China, the weakest of China’s big banks and the last to go public, to sell what was initially pegged at $30 billion in new stock would be a huge vote of confidence in China’s ability to meet both those goals. (For more on this indicator see my post http://jubakpicks.com/2010/06/07/when-to-buy-chinas-stocks-my-leading-indicator-still-looks-positive-for-july-but-the-reading-is-foggier/ )
However, towever, Hhe IPO market in Hong Kong isn’t looking especially favorable to this IPO right now. Five companies have pulled about $3.8 billion in potential initial public offerings from the pipeline in the last few weeks because of a faltering market. (For more on the role of real estate in that market weakness se my post http://jubakpicks.com/2010/06/16/332-million-real-estate-sale-collapses-in-hong-kong-more-to-come/ )
The latest deal to get pulled is the $1.2 billion IPO of China’s second-biggest wind turbine manufacturer Xinjiang Goldwind Science & Technology.
But there’s good news on the Agricultural Bank of China offering too.
The Beijing government clearly wants this IPO to go to market and is pulling out all the stops to line up big investors for the shares. Latest to sign on are Cheung Kong Holdings chairman Li Ka-shing, the third richest individual in Asia, and Henderson Land chairman Lee Shau Kee, the fourth richest individual in Asia.
The bank has begun pre-marketing its IPO, a process that involves providing more financial information and forecasts to analysts and investors who are trying to put a value on the company. Right now it looks like the offering will bring in something less than the initial $30 billion estimate and something more than the recent $20 billion projection.
The Hong Kong H-share offering is scheduled to begin trading on July 16.
Related Articles on STOCKS
Cancer has long been a scourge of humankind and treatments and/or cures have always been iffy becaus...
With so much political and global uncertainty, it doesn’t look like this market volatility is ...
2018 was a difficult year for The Medicines Company (MDCO) with the stock languishing as biotech inv...